Royalty Pharma PLC
NASDAQ:RPRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Royalty Pharma PLC
NASDAQ:RPRX
|
US |
|
Beijing Vastdata Technology Co Ltd
SSE:603138
|
CN |
|
C
|
Colowide Co Ltd
TSE:7616
|
JP |
|
WH Ireland Group PLC
LSE:WHI
|
UK |
|
A
|
Autoline Industries Ltd
NSE:AUTOIND
|
IN |
|
H
|
Hudaco Industries Ltd
JSE:HDC
|
ZA |
|
Cerillion PLC
LSE:CER
|
UK |
|
ChargePoint Holdings Inc
NYSE:CHPT
|
US |
|
Macquarie Korea Infrastructure Fund
KRX:088980
|
KR |
|
A
|
Avid Technology Inc
F:AVD
|
US |
Wall Street
Price Targets
RPRX Price Targets Summary
Royalty Pharma PLC
According to Wall Street analysts, the average 1-year price target for
RPRX
is 53.03 USD
with a low forecast of 46.46 USD and a high forecast of 64.05 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is RPRX's stock price target?
Price Target
53.03
USD
According to Wall Street analysts, the average 1-year price target for
RPRX
is 53.03 USD
with a low forecast of 46.46 USD and a high forecast of 64.05 USD.
What is Royalty Pharma PLC's Revenue forecast?
Projected CAGR
16%
For the last 7 years the
compound annual growth rate for
Royalty Pharma PLC's revenue is
4%.
The projected
CAGR
for the next 3 years is
16%.
What is Royalty Pharma PLC's Operating Income forecast?
Projected CAGR
25%
For the last 7 years the
compound annual growth rate for
Royalty Pharma PLC's operating income is
2%.
The projected
CAGR
for the next 3 years is
25%.
What is Royalty Pharma PLC's Net Income forecast?
Projected CAGR
67%
For the last 7 years the
compound annual growth rate for
Royalty Pharma PLC's net income is
-8%.
The projected
CAGR
for the next 3 years is
67%.
